These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37939991)

  • 21. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
    Myhre PL; Liu Y; Kulac IJ; Claggett BL; Prescott MF; Felker GM; Butler J; Piña IL; Rouleau JL; Zile MR; McMurray JJV; Ward JH; Solomon SD; Januzzi JL
    Eur J Heart Fail; 2023 Aug; 25(8):1396-1405. PubMed ID: 37401523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
    Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
    Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects and mechanism of Compound Qidan Formula on rats with HFpEF induced by hypertension and diabetes mellitus based on Ang Ⅱ/TGF-β1/Smads signaling pathway.
    Yuan P; Liu J; Xiong S; Yang L; Guan J; Dong G; Shi D
    J Ethnopharmacol; 2023 Sep; 313():116558. PubMed ID: 37116729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
    Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.
    Martínez-Falguera D; Aranyó J; Teis A; Ferrer-Curriu G; Monguió-Tortajada M; Fadeuilhe E; Rodríguez-Leor O; Díaz-Güemes I; Roura S; Villuendas R; Sarrias A; Bazan V; Delgado V; Bayes-Genis A; Bisbal F; Gálvez-Montón C
    Circ Arrhythm Electrophysiol; 2024 May; 17(5):e012517. PubMed ID: 38666379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
    Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
    J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
    J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
    Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
    Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simvastatin Attenuates Cardiac Fibrosis under Pathophysiological Conditions of Heart Failure with Preserved Left Ventricular Ejection Fraction by Inhibiting TGF-β Signaling.
    Marunouchi T; Matsumura K; Fuji E; Iwamoto A; Tanonaka K
    Pharmacology; 2024; 109(1):43-51. PubMed ID: 38016432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction.
    Li BH; Fang KF; Lin PH; Zhang YH; Huang YX; Jie H
    Clin Hemorheol Microcirc; 2021; 77(4):425-433. PubMed ID: 33386797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Burke RM; Lighthouse JK; Mickelsen DM; Small EM
    Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
    Gori M; D'Elia E; Senni M
    Int J Cardiol; 2019 Apr; 281():158-165. PubMed ID: 30420146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
    Zhang Y; Yuan M; Suo Y; Yang Q; Shao S; Li Y; Wang Y; Bao Q; Liu T; Li G
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):848-857. PubMed ID: 35596518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
    Raschi E; Diemberger I; Sabatino M; Poluzzi E; De Ponti F; Potena L
    Expert Opin Pharmacother; 2022 Feb; 23(3):303-320. PubMed ID: 35050813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction.
    de Couto G; Mesquita T; Wu X; Rajewski A; Huang F; Akhmerov A; Na N; Wu D; Wang Y; Li L; Tran M; Kilfoil P; Cingolani E; Marbán E
    Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H892-H903. PubMed ID: 36083797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.